CA2390646A1 - Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes - Google Patents
Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes Download PDFInfo
- Publication number
- CA2390646A1 CA2390646A1 CA002390646A CA2390646A CA2390646A1 CA 2390646 A1 CA2390646 A1 CA 2390646A1 CA 002390646 A CA002390646 A CA 002390646A CA 2390646 A CA2390646 A CA 2390646A CA 2390646 A1 CA2390646 A1 CA 2390646A1
- Authority
- CA
- Canada
- Prior art keywords
- organelle
- atp
- cells
- sequence
- mitochondria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16462299P | 1999-11-10 | 1999-11-10 | |
US60/164,622 | 1999-11-10 | ||
PCT/US2000/030862 WO2001034833A2 (en) | 1999-11-10 | 2000-11-10 | Regulating endogenous inhibitor at atp synthase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2390646A1 true CA2390646A1 (en) | 2001-05-17 |
Family
ID=22595338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002390646A Abandoned CA2390646A1 (en) | 1999-11-10 | 2000-11-10 | Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1230379A2 (ja) |
JP (1) | JP2003527835A (ja) |
AU (1) | AU1759901A (ja) |
CA (1) | CA2390646A1 (ja) |
WO (1) | WO2001034833A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072739A1 (en) * | 1999-11-10 | 2004-04-15 | Anderson Christen M. | Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes |
CA2422671A1 (en) * | 2000-09-20 | 2002-03-28 | Mitokor | Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
US7470542B2 (en) | 2001-09-05 | 2008-12-30 | Pride Proteomics A/S | Proteins in type 2 diabetes |
KR102239074B1 (ko) * | 2018-09-14 | 2021-04-14 | 고려대학교 산학협력단 | IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물 |
KR102239075B1 (ko) * | 2018-10-02 | 2021-04-14 | 고려대학교 산학협력단 | IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물 |
KR102248110B1 (ko) * | 2018-10-02 | 2021-05-06 | 고려대학교 산학협력단 | IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 항암용 약학 조성물 |
KR102276379B1 (ko) * | 2018-10-02 | 2021-07-14 | 고려대학교 산학협력단 | IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물 |
MX2023007788A (es) * | 2021-01-24 | 2023-11-17 | Michael David Forrest | Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
WO1998033909A1 (en) * | 1997-01-31 | 1998-08-06 | Incyte Pharmaceuticals, Inc. | Novel human atpase inhibitor protein |
GB9824282D0 (en) * | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
US6140067A (en) * | 1999-04-30 | 2000-10-31 | Mitokor | Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
-
2000
- 2000-11-10 EP EP00980320A patent/EP1230379A2/en not_active Withdrawn
- 2000-11-10 JP JP2001536758A patent/JP2003527835A/ja not_active Withdrawn
- 2000-11-10 AU AU17599/01A patent/AU1759901A/en not_active Abandoned
- 2000-11-10 CA CA002390646A patent/CA2390646A1/en not_active Abandoned
- 2000-11-10 WO PCT/US2000/030862 patent/WO2001034833A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2001034833A2 (en) | 2001-05-17 |
AU1759901A (en) | 2001-06-06 |
EP1230379A2 (en) | 2002-08-14 |
WO2001034833A3 (en) | 2002-01-17 |
JP2003527835A (ja) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040072739A1 (en) | Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes | |
US20020049176A1 (en) | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery | |
Seibel et al. | Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases | |
KR102544051B1 (ko) | 인간화된 ttr 유전자좌를 포함하는 비인간 동물 및 사용 방법 | |
JP2021534798A (ja) | ゲノムを調節するための方法及び組成物 | |
BR112020005323A2 (pt) | polinucleotídeos, composições e métodos para edição de genoma | |
US7223556B1 (en) | Targeted proteolysis by recruitment to ubiquitin protein ligases | |
US8993741B2 (en) | SMNdelta7 degron: novel compositions and methods of use | |
US20200362008A1 (en) | Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits | |
US20230151342A1 (en) | Zinc finger degradation domains | |
KR20220004065A (ko) | 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물 | |
CA2390646A1 (en) | Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes | |
WO2001035096A2 (en) | Diseases associated with altered mitochondrial function | |
US20030026781A1 (en) | Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes | |
US20100310532A1 (en) | Gene targets in anti-aging therapy and tissue repair | |
Boustead et al. | Identification and characterization of a cDNA and the gene encoding the mouse ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein | |
SE523043C2 (sv) | Humant intestinalt Npt2B | |
US6084063A (en) | Signal transduction inhibitors of allergic reactions | |
EP0984987A2 (en) | A soluble laminin receptor precursor and methods to ihnibit its interactions | |
JP2020529836A (ja) | ミオパチーの処置における使用のためのmtmr2−sポリペプチド | |
EP1161442A2 (en) | Exocytosis pathway proteins and methods of use | |
US9243234B2 (en) | Sequence-specific MRNA interferase and uses thereof | |
Pinello et al. | Novel requirements for HAP2/GCS1-mediated gamete fusion in Tetrahymena. | |
JP4488720B2 (ja) | アポトーシス関連蛋白質およびその用途 | |
RU2784927C1 (ru) | Отличные от человека животные, включающие в себя гуманизированный ttr локус, и способы применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |